EyePoint, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
14.93
+0.12 (0.81%)
At close: Apr 17, 2026, 4:00 PM EDT
14.93
0.00 (0.00%)
After-hours: Apr 17, 2026, 6:19 PM EDT
EyePoint Employees
EyePoint had 214 employees as of December 31, 2025. The number of employees increased by 49 or 29.70% compared to the previous year.
Employees
214
Change (1Y)
49
Growth (1Y)
29.70%
Revenue / Employee
$146,593
Profits / Employee
-$1,083,935
Market Cap
1.25B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 214 | 49 | 29.70% | 214 | 0 |
| Dec 31, 2024 | 165 | 44 | 36.36% | 165 | 0 |
| Dec 31, 2023 | 121 | -23 | -15.97% | 121 | 0 |
| Dec 31, 2022 | 144 | 21 | 17.07% | 144 | 0 |
| Dec 31, 2021 | 123 | 22 | 21.78% | 122 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Pharming Group | 407 |
| Zenas BioPharma | 167 |
| MapLight Therapeutics | 133 |
| MoonLake Immunotherapeutics | 130 |
| Septerna | 130 |
| DBV Technologies | 117 |
| Inhibrx Biosciences | 110 |
EYPT News
- 3 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - EyePoint sues rival Ocular Therapeutix, alleging false claims about eye drug - Reuters
- 6 weeks ago - EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 6 weeks ago - EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema - GlobeNewsWire
- 7 weeks ago - EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026 - GlobeNewsWire
- 7 weeks ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - EyePoint Appoints Michael Campbell as Chief Commercial Officer - GlobeNewsWire
- 2 months ago - EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire